Sean E. Collins

发表

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

H. Jessen, R. Grant, K. Mounzer, 2020, The Lancet.

Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants.

K. White, D. Brainard, Ross Martin, 2021, The Journal of antimicrobial chemotherapy.

Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients

R. Shafer, P. Grant, S. Collins, 2015, Drugs.

Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus

D. Ward, P. Sax, Y. Yazdanpanah, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individuals

M. Kozal, H. Günthard, S. Little, 2021, AIDS.

Lack of an association between clinical INSTI-related body weight gain and direct interference with MC4 receptor (MC4R), a key central regulator of body weight

K. White, M. Das, L. A. Burns-Naas, 2020, PloS one.

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.

D. Podzamczer, H. Stellbrink, P. Sax, 2020, The lancet. HIV.

Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.

H. Stellbrink, P. Sax, H. Albrecht, 2019, The lancet. HIV.

Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.

Y. Yazdanpanah, A. Antinori, A. Clarke, 2019, The lancet. HIV.

Integrating Integrase Inhibitors Into an Antiretroviral Regimen

A. Zolopa, P. Grant, S. Collins, 2014, Current Treatment Options in Infectious Diseases.

Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials.

K. White, C. Orkin, C. Kityo, 2021, Journal of acquired immune deficiency syndromes.

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-Existing NRTI Resistance.

K. White, Ross Martin, Hal Martin, 2020, Journal of acquired immune deficiency syndromes.

Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide

D. Ward, P. Sax, A. Cheng, 2018, AIDS.

A Randomized Switch From Nevirapine-Based Antiretroviral Therapy to Single Tablet Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed Human Immunodeficiency Virus-1-Infected Rwandans

A. Zolopa, P. Grant, S. Nsanzimana, 2016, Open forum infectious diseases.

High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I

K. White, P. Sax, J. Gallant, 2022, AIDS.